MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.
$2.33+4.96%
报价 2026-11-06
市值
$148.4M
EV
$76.6M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -52.1%
$1.33$4.86
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MGNXMacroGenics, Inc. | $148.4M | +5.0% | -21.0% | 50.4% | – | – | – | |
| OVIDOvid Therapeutics Inc. | $556.6M | +10.5% | -97.0% | 100% | – | – | – | |
| STTKShattuck Labs, Inc. | $463.7M | +2.9% | +33.3% | -82% | – | – | – | |
| IFRXInflaRx N.V. | $192.3M | -3.7% | – | 48,201.6% | – | – | – | |
| WHWKWhitehawk Therapeutics Inc | $178.4M | +3.6% | +23.9% | 0% | – | – | – | |
| ORMPOramed Pharmaceuticals Inc. | $160.6M | -0.8% | -40.0% | 0% | 1.9x | 2.4x | – | |
| ZNTLZentalis Pharmaceuticals, Inc. | $122.4M | +0.6% | -22.2% | 0% | – | – | – | |
| COYACoya Therapeutics, Inc. | $70.1M | +6.4% | -61.0% | 99.8% | – | – | – | |
| CLNNClene Inc. | $56.1M | -0.5% | +100.0% | -110.1% | – | – | – | |
| 同行中位数 | – | – | -22.2% | 0% | 1.9x | 2.4x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。